AEON Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
AEON Biopharma, Inc. (AEON), a Delaware corporation, filed this Current Report on Form 8-K on October 7, 2024. The Company is an emerging growth company with its principal executive offices in Irvine, California. Its Class A Common Stock trades on the NYSE American under the symbol "AEON."
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report serves solely to disclose the release of a corporate presentation.
Material Changes
No material financial changes or operational updates are detailed within the text of this filing. The report references a new corporate presentation (Exhibit 99.1) made available on the Company's investor relations website.
Guidance, Outlook, and Risks
The filing notes that the attached Corporate Presentation contains forward-looking statements. Management indicated that information from this presentation may be used in future meetings. The filing explicitly states that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference unless specifically referenced in another filing.
Key Facts for Investor Verification
- Verify the content of the Corporate Presentation (Exhibit 99.1) on the Company's investor relations website for specific business updates.
- Review the "Forward-Looking Statements" slide within Exhibit 99.1 for associated risks and assumptions.
- Confirm that this 8-K does not constitute a filing of financial data under Section 18 of the Exchange Act.
- Note the Company's status as an emerging growth company.